Ipamorelin UK: Growth Hormone Secretagogue Research Guide

Ipamorelin is a selective growth hormone secretagogue peptide and one of the most researched compounds in anti-ageing, body composition, and recovery research. Its selectivity for GH release without significant cortisol or prolactin stimulation makes it a preferred choice in many UK research protocols.

What Is Ipamorelin?

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide growth hormone releasing peptide (GHRP) developed by Novo Nordisk in the late 1990s. Unlike earlier GHRPs such as GHRP-2 and GHRP-6, Ipamorelin exhibits high selectivity — stimulating GH release via ghrelin receptor (GHS-R1a) agonism without meaningfully elevating ACTH, cortisol, aldosterone, or prolactin at research doses. This selectivity profile has made it one of the most studied GHRPs in the anti-ageing and regenerative medicine research space.

Mechanism of Action

Ipamorelin binds to the growth hormone secretagogue receptor (GHS-R1a) on pituitary somatotroph cells, triggering a pulsatile release of endogenous growth hormone that mimics the body's natural GH secretion pattern. Crucially, it does not suppress somatostatin signalling or desensitise GH receptors over time in the way that exogenous HGH administration can. This mechanism makes it particularly interesting for research into GH restoration approaches that preserve pituitary feedback loops.

Research Applications

Published research has explored Ipamorelin across several domains:

• Age-related GH decline (somatopause) models — rodent studies showing GH pulse restoration
• Body composition research — lean mass preservation and fat metabolism studies
• Bone density — studies showing IGF-1-mediated increases in bone mineral density markers
• Post-operative recovery — GI motility restoration research following abdominal surgery (Ipamorelin was the first GHRP to enter clinical trials for postoperative ileus)
• Sleep quality — GH pulses during slow-wave sleep amplification studies

Dosing in Research

Research protocols typically use 200–300mcg per injection, administered 1–3 times daily via subcutaneous injection, often timing administration around sleep and training windows to align with natural GH pulse rhythms. Cycle lengths of 8–12 weeks are common in published literature, with some protocols running 16–24 weeks for longer-term metabolic endpoints.

Ipamorelin + CJC-1295 Combination

A commonly studied combination pairs Ipamorelin with CJC-1295 (a GHRH analogue), as the two peptides act on complementary pathways — Ipamorelin through GHS-R1a and CJC-1295 through GHRH receptors — producing synergistic GH release amplification in rodent models. Both compounds are available from Alluvi.

Buy Ipamorelin UK

Alluvi supplies pharmaceutical-grade Ipamorelin from GMP-certified manufacturers, independently tested to ≥98% purity by HPLC. Order Ipamorelin UK with free shipping. Min order £100.